Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System

The successful implementation of chimeric antigen receptor (CAR)-T cell therapy in the clinical context of B cell malignancies has paved the way for further development in the more critical setting of acute myeloid leukemia (AML). Among the potentially targetable AML antigens, CD33 is insofar one of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Ther
Hauptverfasser: Rotiroti, Maria Caterina, Buracchi, Chiara, Arcangeli, Silvia, Galimberti, Stefania, Valsecchi, Maria Grazia, Perriello, Vincenzo Maria, Rasko, Tamas, Alberti, Gaia, Magnani, Chiara Francesca, Cappuzzello, Claudia, Lundberg, Felix, Pande, Amit, Dastoli, Giuseppe, Introna, Martino, Serafini, Marta, Biagi, Ettore, Izsvák, Zsuzsanna, Biondi, Andrea, Tettamanti, Sarah
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Gene & Cell Therapy 2020
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7474266/
https://ncbi.nlm.nih.gov/pubmed/32526203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.05.021
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge